Acetyl tetrapeptide-5
is used in cosmetic eye formulations to decrease puffiness, eye bags, and dark circles by reducing edema and protecting proteins such as SOD from glycation
Alanine
Ala / A · hydrophobic residue · neutral charge
AOD-9604
is studied as an anti-obesity peptide that can reduce weight gain and increase fat oxidation in obese animal models with generally neutral effects on IGF-1 and glucose metabolism in early human trials
Arginine
Arg / R · basic residue · positive charge
Argireline
is a topical cosmetic peptide reported to decrease dynamic wrinkles by partially mimicking the mechanism of botulinum toxin in a non-invasive manner
Asparagine
Asn / N · polar residue · neutral charge
Aspartic acid
Asp / D · acidic residue · negative charge
BPC-157
is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects
Comparison
While BPC-157 is investigated for accelerating healing of gastrointestinal mucosa, tendons, ligaments, bone, and nervous tissue in preclinical models, with anti-inflammatory and pro-angiogenic effects111, Tirzepatide is approved for type 2 diabetes and obesity, producing larger HbA1c and body-weight reductions than semaglutide in head-to-head trials24.
While BPC-157 works as a synthetic 15-amino-acid fragment of a gastric cytoprotective protein that promotes angiogenesis and tissue protection primarily by modulating VEGFR2 signaling, Src/caveolin-1–dependent eNOS activation, and nitric oxide production111, Tirzepatide is a 39-amino-acid synthetic peptide primarily based on GIP sequence with C20 fatty diacid conjugation that acts as a dual agonist at GIP and GLP-1 receptors, enhancing glucose-dependent insulin secretion, suppressing glucagon, delaying gastric emptying, and reducing appetite24.
BPC-157
Not assigned in the current dataset.
Tirzepatide
Not assigned in the current dataset.
BPC-157 and Tirzepatide are noticeably different, with limited direct overlap in their usual biological context. Their typical research and application settings separate fairly clearly: BPC-157 is more often discussed in the realm of Gastroenterology, Musculoskeletal health, and Dermatology and aesthetics, whereas Tirzepatide is more often associated with the realm of Metabolic and endocrine and Cardiovascular health. Their biological logic is quite different: BPC-157 is a signaling modulator, whereas Tirzepatide is a receptor agonist and a hormone analog. Both are synthetic in origin and their development context also differs, with BPC-157 in Preclinical development while Tirzepatide is approved. BPC-157 takes the form of a linear peptide, whereas Tirzepatide is closer to a peptide conjugate, Tirzepatide incorporates lipidation and d-amino acid substitution features that are not part of BPC-157; while their sequence patterns also diverge, with BPC-157 showing proline-rich features and Tirzepatide showing alpha-helical domain features.